Patents by Inventor Shalini Singh
Shalini Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240160500Abstract: Conversations with software applications have been an integral part of day-to-day activities. For a smooth conversations, it is necessary for a software to automatically help in understanding another software. A method and system for enabling conversational reverse engineering and understanding of software application has been provided. The present disclosure proposes a solutions which is configured to build a dynamic knowledge base for a bot to learn from an input application source code. The system and method are further configured to provide functional/domain context-based question interpretation and mapping of the information to the dynamically built knowledge base. A user query is converted to a proprietary question model. Further, a question verb, primary entity and secondary entity are extracted through natural language processing.Type: ApplicationFiled: November 21, 2023Publication date: May 16, 2024Applicant: Tata Consultancy Services LimitedInventors: Yogananda RAVINDRANATH, Tamildurai MEHALINGAM, Shrayan BANERJEE, Pranav Bhaskar KONDURU, Shalini SINGH, Balakrishnan VENKATANARAYANAN
-
Patent number: 11899514Abstract: Described herein are systems, methods, and software to manage power consumption in a software build environment. In one implementation, a monitoring service monitors power consumption information associated with a build environment for one or more software components. The monitoring service further identifies one or more trends associated with the power consumption information based at least on the power consumption information satisfying one or more criteria and generates a summary for display that indicates at least the one or more trends. The monitoring service may also identify and display as part of the summary one or more suggestions to improve power consumption based on the one or more trends.Type: GrantFiled: April 25, 2022Date of Patent: February 13, 2024Assignee: VMware LLCInventors: Shalini Singh, Sairam Veeraswamy, Adarsh Jagadeeshwaran, Joshua Philip Schnee, Vijayaraghavan Soundararajan, Shiva Ds, Harsh Hirani, Priya Kalaiselvan, Shashank Rai
-
Publication number: 20240041761Abstract: A film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and one or more cannabinoids, such as ?9-tetrahydrocannabinol (THC) or cannabidiol (CBD), or pharmaceutically acceptable salts thereof is described. Methods for manufacturing such a film, and the use of such a film in the treatment of disease are also described.Type: ApplicationFiled: July 26, 2023Publication date: February 8, 2024Inventors: Scott Boyer, Fredrik Hübinette, Shalini Singh
-
Publication number: 20240027463Abstract: The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.Type: ApplicationFiled: July 12, 2023Publication date: January 25, 2024Inventors: Fernando Jose Rebelo do Couto, Zhiming Liao, Andrea Muranyi, Kandavel Shanmugam, Shalini Singh, Yifei Zhu
-
Publication number: 20230340147Abstract: The present invention relates to an antibody or an antigen binding fragment thereof that specifically binds to ?-1,6-core-fucosylated prostate specific antigen (PSA) and partial sequences thereof comprising the ?-1,6-core-fucose residue. The antibodies and antigen binding fragments significantly discriminate between core-fucosylated PSA or core-fucosylated PSA partial sequences and other glycosylated PSA species and partial sequences thereof lacking the core-fucose residue, including aglycosylated PSA, as well as core-fucosylated glycan in other contexts. The present invention further relates to nucleic acid molecules encoding the light chain variable region or the heavy chain variable region of the antibody of the invention, as well as vectors comprising said nucleic acid molecules.Type: ApplicationFiled: March 21, 2023Publication date: October 26, 2023Inventors: Magdalena Swiatek-de Lange, Joanna Siebenhaar, Carol Jones, Thomas Pritchett, Andrea Muranyi, Caroline Dorothea Hojer, Michael Gerg, Lars Hillringhaus, Gloria Tabares, Christian Roessler, Michael Schraeml, Shalini Singh, Theresa Kott
-
Publication number: 20230280345Abstract: Methods allowing prediction of a response to anti-EGFR therapies are provided, which include histochemical or cytochemical staining methods for staining amphiregulin (AREG) or epiregulin (EREG). Scoring algorithms are provided that may include but are not limited to determining a percent tumor cell positivity for each of EREG and AREG and comparing the determined percent positivity to pre-determined cut offs. The pre-determined cut offs can be either positive cut offs (in which case patients are treated with the EGFR-directed therapy if the percentage is greater than or equal to the cut off), negative cut offs (in which case patients are not treated with the EGFR-directed therapy if the percentage is less than the cut off), or both a positive and negative cut off.Type: ApplicationFiled: March 20, 2023Publication date: September 7, 2023Inventors: ISAAC YUYU BAI, JENNIFER HELEN BARRETT, FAYE ELLIOTT, WEN-WEI LIU, PHILIP QUIRKE, SUSAN DIANE RICHMAN, JENNIFER FRANCES SELIGMANN, MATTHEW THOMAS SEYMOUR, KANDAVEL SHANMUGAM, SHALINI SINGH, NICHOLAS PAUL WEST, CHRISTOPHER JAMES MICHAEL WILLIAMS, LIPING ZHANG
-
Patent number: 11747339Abstract: The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.Type: GrantFiled: October 21, 2020Date of Patent: September 5, 2023Assignee: Ventana Medical Systems, Inc.Inventors: Fernando Jose Rebelo do Couto, Zhiming Liao, Andrea Muranyi, Kandavel Shanmugam, Shalini Singh, Yifei Zhu
-
Publication number: 20230273807Abstract: A power optimization system may include a cloud management server coupled to a plurality of clusters via a network, a resource management module residing in the cloud management server, and a cloud power optimizer module residing in the resource management module. Each cluster may include a plurality of physical hosts with at least one virtual machine (VM) running on each physical host. During operation, the cloud power optimizer module may determine background and active power usages of each physical host in the plurality of clusters. Further, the cloud power optimizer module may determine power usage of each VM based on the determined background and active power usages of each physical host. Furthermore, the cloud power optimizer module may continuously balance a distribution of workload on the plurality of physical hosts based on the determined power usage of each VM.Type: ApplicationFiled: April 28, 2022Publication date: August 31, 2023Inventors: VENU MAHESH UPPALAPATI, Sairam Veeraswamy, Adarsh Jagadeeshwaran, Shalini Singh
-
Publication number: 20230229219Abstract: Described herein are systems, methods, and software to manage power consumption in a software build environment. In one implementation, a monitoring service monitors power consumption information associated with a build environment for one or more software components. The monitoring service further identifies one or more trends associated with the power consumption information based at least on the power consumption information satisfying one or more criteria and generates a summary for display that indicates at least the one or more trends. The monitoring service may also identify and display as part of the summary one or more suggestions to improve power consumption based on the one or more trends.Type: ApplicationFiled: April 25, 2022Publication date: July 20, 2023Inventors: Shalini Singh, Sairam Veeraswamy, Adarsh Jagadeeshwaran, Joshua Philip Schnee, Vijayaraghavan Soundararajan, Shiva Ds, Harsh Hirani, Priya Kalaiselvan, Shashank Rai
-
Publication number: 20230184772Abstract: Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.Type: ApplicationFiled: October 7, 2022Publication date: June 15, 2023Inventors: Michael Barnes, June F. Clements, Thomas Grogan, Hiro Nitta, Esteban Roberts, Crystal Schemp, Shalini Singh, Penny Towne
-
Patent number: 11499974Abstract: Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.Type: GrantFiled: March 13, 2020Date of Patent: November 15, 2022Assignee: Ventana Medical Systems, Inc.Inventors: Michael Barnes, June F. Clements, Thomas Grogan, Hiro Nitta, Esteban Roberts, Crystal Schemp, Shalini Singh, Penny Towne
-
Publication number: 20220051804Abstract: Heterogeneity for biomarkers in a tissue sample can be calculated. A heterogeneity score can be combined with an immunohistochemistry combination score to provide breast cancer recurrence prognosis. Heterogeneity can be based on percent positivity determinations for a plurality of biomarkers according to how many cells in the sample stain positive. An immunohistochemistry combination score can be calculated. An imaging tool can support a digital pathologist workflow that includes designating fields of view in an image of the tissue sample. Based on the fields of view, a heterogeneity metric can be calculated and combined with an immunohistochemistry combination score to generate a breast cancer recurrence prognosis score.Type: ApplicationFiled: October 28, 2021Publication date: February 17, 2022Inventors: Srinivas Chukka, Olcay Sertel, Anindya Sarkar, Nikolaus Wick, Shalini Singh, Crystal Schemp, Paul Waring, Raymond Tubbs
-
Patent number: 11211167Abstract: Heterogeneity for biomarkers in a tissue sample can be calculated. A heterogeneity score can be combined with an immunohistochemistry combination score to provide breast cancer recurrence prognosis. Heterogeneity can be based on percent positivity determinations for a plurality of biomarkers according to how many cells in the sample stain positive. An immunohistochemistry combination score can be calculated. An imaging tool can support a digital pathologist workflow that includes designating fields of view in an image of the tissue sample. Based on the fields of view, a heterogeneity metric can be calculated and combined with an immunohistochemistry combination score to generate a breast cancer recurrence prognosis score.Type: GrantFiled: December 19, 2013Date of Patent: December 28, 2021Assignees: VENTANA MEDICAL SYSTEMS, INC., THE CLEVELAND CLINIC FOUNDATION, THE UNIVERSITY OF MELBOURNEInventors: Srinivas Chukka, Olcay Sertel, Anindya Sarkar, Nikolaus Wick, Shalini Singh, Crystal Schemp, Paul Waring, Raymond Tubbs
-
Publication number: 20210346277Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and one or more cannabinoids, such as ?9-tetrahydrocannabinol (THC) or cannabidiol (CBD), or pharmaceutically acceptable salts thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of disease.Type: ApplicationFiled: May 15, 2019Publication date: November 11, 2021Inventors: Scott Boyer, Fredrik Hübinette, Shalini Singh
-
Publication number: 20210063403Abstract: The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.Type: ApplicationFiled: October 21, 2020Publication date: March 4, 2021Inventors: Fernando Jose Rebelo do Couto, Zhiming Liao, Andrea Muranyi, Kandavel Shanmugam, Shalini Singh, Yifei Zhu
-
Patent number: 10852304Abstract: The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.Type: GrantFiled: December 21, 2017Date of Patent: December 1, 2020Assignee: Ventana Medical Systems, Inc.Inventors: Fernando Jose Rebelo do Couto, Zhiming Liao, Andrea Muranyi, Kandavel Shanmugam, Shalini Singh, Yifei Zhu
-
Patent number: 10755406Abstract: Described herein are methods for co-expression analysis of multiple markers in a tissue sample comprising: computing a heat map of marker expression for each of a plurality of single marker channel images, wherein each of the plurality of single marker channel images comprise a single marker; identifying one or more candidate regions of interest in each heat map of marker expression; computing overlay masks comprising the identified one or more candidate regions of interest from each heat map of marker expression; determining one or more co-localized regions of interest from the overlay masks; mapping the one or more co-localized regions of interest to a same coordinate position in each of the plurality of single marker channel images; and estimating a number of cells in at least one of the determined one or more co-localized regions of interest in each of the plurality of single marker channel images.Type: GrantFiled: June 30, 2017Date of Patent: August 25, 2020Assignee: Ventana Medical Systems, Inc.Inventors: Michael Barnes, Christophe Chefd'hotel, Ting Chen, Shalini Singh, Alisa Tubbs
-
Publication number: 20200225237Abstract: Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.Type: ApplicationFiled: March 13, 2020Publication date: July 16, 2020Inventors: Michael Barnes, June F. Clements, Thomas Grogan, Hiro Nitta, Esteban Roberts, Crystal Schemp, Shalini Singh, Penny Towne
-
Patent number: 10620207Abstract: Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.Type: GrantFiled: March 31, 2017Date of Patent: April 14, 2020Assignee: Ventana Medical Systems, Inc.Inventors: Thomas Grogan, Hiro Nitta, Michael Barnes, Penny Towne, Shalini Singh, June F. Clements, Crystal Schemp, Esteban Roberts
-
Publication number: 20190269716Abstract: A combination of mismatch repair (MMR) and Metastasis Associated in Colon Cancer 1 (MACC1) gene expression status of the patient serve as a basis for risk stratification of early stage colon cancer patients. Patients with defective MMR (dMMR) status have improved survival and do not benefit from 5-fluorouracil (5-FU) therapies. In contrast, patients with a proficient MMR (pMMR) status have a higher risk of recurrence and worse survival. The pMMR patients are then further stratified on the basis of MACC1 gene expression. Patients with a pMMR status and a low MACC1 expression have a favorable prognosis similar to patients having a dMMR status, whereas patients having a pMMR status and high MACC1 expression have a less favorable prognosis.Type: ApplicationFiled: May 14, 2019Publication date: September 5, 2019Inventors: Pia Herrmann, Katharina Ilm, Katherine F. Leith, Andrea Muranyi, Ulrich-Peter Rohr, Kandavel Shanmugam, Shalini Singh, Ulrike Stein